Discovery Newsletter: April 2023
In this month’s newsletter, learn more about our comprehensive panel of CDK4/6 inhibitor-resistant breast cancer models and in vitro imaging assays for compound profiling. We also showcase our recent publications describing the development of HBV antigen inhibitors and noncovalent inhibitors of the SARS-CoV-2 3C-like protease (3CLpro).
Related Content
Strategies to stimulate dendritic cell (DC) activity, such as ex vivo generation and priming of DC vaccines, have been explored...
VIEW RESOURCEIntroduction: RNA-based therapies are a frontier in biomedicine, with the potential to fundamentally change treatments for a wide range of...
VIEW RESOURCE